News

The approval will enable ViiV Healthcare to use the complete regimen as a replacement for the current antiretroviral (ARV) regimen in adults who are virologically suppressed on a

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, in

The results were reviewed by an independent Data Monitoring Committee (DMC) at a planned interim analysis. The safety profile for lorlatinib and crizotinib were consistent with what has

BLENREP has been approved as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have secured at least four prior therapies including an anti-CD38

“With its advanced Hyperimmune Library series, rapid discovery cycle and high throughput antibody expression capabilities, Twist is an ideal partner for accelerating our quest to develop best-in-class bispecific

The companies said that rapid recovery was seen in patients on ventilators and extracorporeal membrane oxygenation (ECMO) and having severe medical comorbidities following three days of treatment with

HEPCLUDEX has been approved as the first treatment option for adult patients with chronic hepatitis delta virus infection and compensated liver disease in Europe. The drug was originally

Sisunatovir is an orally administered fusion inhibitor designed to inhibit RSV replication by suppressing RSV F-mediated fusion of RSV with the host cell. RSV is a respiratory pathogen

Calidi has partnered with PSC for over two years—most recently contributing the stem cell lines used to manufacture treatment for the upcoming first trial, “CoronaStem 1,” which will